Surface‐Capped Protein Nanoparticles for Nonviral Gene Delivery
Advanced Materials · 2026-04 · 38 (20)
DOI: 10.1002/adma.202521796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 12.03.2026. Verfasst von Fjorela Xhyliu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Nanoparticles, Gene Transfer Techniques, Serum Albumin. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Developing simple, safe, and efficient nonviral delivery systems remains a significant challenge in bioengineering. Nanoparticles offer promising gene delivery capabilities with reduced toxicity; however, long‐standing challenges related to effective plasmid encapsulation and delivery exist. Here, we report a novel protein‐based nanoparticle platform prepared by electrohydrodynamic jetting that features effective plasmid encapsulation and release. The protein, serum albumin, acts as the structural component of the nanoparticle and encapsulates the plasmid. To avoid chemical cross‐linking, the protein‐based nanoparticles are surface‐capped via interfacial complexation with a polycationic polymer. Surface‐capped protein nanoparticles (scPNPs) show excellent stability for 12 days at physiological pH values and have exceptionally high payload ratios of 10% to 40% wt/wt, corresponding to 28–99 plasmids per scPNP. The uptake efficiency of scPNPs exceeds 95% and engages macropinocytosis and clathrin‐mediated endocytosis pathways. When optimizing nonviral gene therapies, either the payload or the nanoparticle dosage can be varied. For scPNPs, increasing the nanoparticle dosage is more effective than increasing the payload, resulting in a 1.6‐fold increase in transfection rate for identical plasmid amounts. To demonstrate their translational potential, scPNPs were used to effectively encapsulate messenger RNA (mRNA) and transfect primary human T cells, while maintaining high cell viability. This work both advances the fundamental understanding of design choices when optimizing nanoparticle‐based gene delivery and demonstrates the potential of scPNPs for cell therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan, USA.
- School of Dentistry, University of Michigan, Ann Arbor, Michigan, USA.
- School of Polymer Science and Engineering, Chonnam National University, Gwangju, South Korea.
- Department of Materials Science and Engineering, University of Michigan, Ann Arbor, Michigan, USA.
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Joerg Lahann
Förderung
- NINDS NIH HHS
- NIH HHS
- NICHD NIH HHS
- NCI NIH HHS
- National Science Foundation
Zitieren
APA
Xhyliu, F., Yao, Y., Ko, Y., Grasman, G., Raymond, J. E., Chang, A., Deng, Y., Dominic, G., Triebwasser, M., & Lahann, J. (2026). Surface‐Capped Protein Nanoparticles for Nonviral Gene Delivery. Advanced Materials, 38(20). https://doi.org/10.1002/adma.202521796
Vancouver
Xhyliu F, Yao Y, Ko Y, Grasman G, Raymond JE, Chang A, et al. Surface‐Capped Protein Nanoparticles for Nonviral Gene Delivery. Advanced Materials. 2026;38(20). doi:10.1002/adma.202521796
BibTeX
@article{Xhyliu2026,
author = {Xhyliu, Fjorela and Yao, Yao and Ko, Yeongun and Grasman, Grant and Raymond, Jeffery E and Chang, Albert and Deng, Yuxuan and Dominic, Grant and Triebwasser, Michael and Lahann, Joerg},
title = {Surface‐Capped Protein Nanoparticles for Nonviral Gene Delivery},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {20},
doi = {10.1002/adma.202521796}
}
EUVIMED